RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay
Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.
RVTY - Revvity, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$108.88
DETAILS
HIGH:
$124.00
LOW:
$95.00
MEDIAN:
$106.00
CONSENSUS:
$108.88
UPSIDE:
12.31%
Stock News
Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This offering complements the Company's FDA-cleared ChLIA tests for free testosterone and sex hormone-binding globulin (SHBG), delivering a first of its kind, complete solution for testosterone-related disorders on a single pla.
RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution
Revvity beat Q1 EPS and revenue estimates as 3% organic growth and portfolio execution offset margin pressure and China ImmunoDx divest plans.
Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript
Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript
Compared to Estimates, Revvity (RVTY) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Revvity (RVTY) Q1 Earnings and Revenues Top Estimates
Revvity (RVTY) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.01 per share a year ago.
Revvity Announces Financial Results for the First Quarter of 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.37, as compared to $0.35 in the same period a year ago. Revenue for the quarter was $711 million, as compared to $665 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $76 million, as compared to $72 million for the same perio.
Revvity to Report Q1 Earnings: What's in Store for the Stock?
RVTY heads into Q1 earnings with Diagnostics strength and Life Sciences stabilization, but China pressures and weak academic demand may temper near-term growth.
Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 7, 2026 to all shareholders of record at the close of business on July 17, 2026. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from dis.
Sumitomo Mitsui Trust Group Inc. Has $3.46 Million Stock Position in Revvity Inc. $RVTY
Sumitomo Mitsui Trust Group Inc. trimmed its position in Revvity Inc. (NYSE: RVTY) by 86.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 35,730 shares of the company's stock after selling 235,296 shares during the quarter. Sumitomo
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: BofA Securities 2026 Health Care Conference Wednesday, May 13, 2026 9:20 a.m. PT - Steve Willoughby, senior vice president, investor relations, ESG, risk Goldman Sachs 47th Annual Global Healthcare Conference Tuesday, June 9, 2026 8:40 a.m. ET - Prahlad Singh, president and chief executive officer Attendees will receive an update on the Company and its strategic pr.
RVTY Unveils Signals BioDesign for Faster Molecular Cloning & R&D Data
Revvity launches Signals BioDesign, a cloud-based cloning platform to streamline biotech R&D workflows and boost collaboration in biologics development.
Revvity to Hold Earnings Call on Tuesday, May 5, 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2026 financial results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the.
Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business is launching Signals BioDesignTM, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D teams, the platform simplifies complex cloning processes and enables scalable, collaborative development in a unified digital environment. It addresses the limitations of desktop tools and overly complex platforms by combining.
Revvity Gains on Diagnostics Strength, Faces China Headwinds
RVTY gains from strong diagnostics and software growth, but China weakness, soft demand, and margin pressures temper its near-term outlook.
Allspring Global Investments Holdings LLC Raises Holdings in Revvity Inc. $RVTY
Allspring Global Investments Holdings LLC increased its position in Revvity Inc. (NYSE: RVTY) by 127.0% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 1,751,612 shares of the company's stock after acquiring an additional 980,142 shares during the quarter. Allspring Global Investments Holdings
Revvity, Inc. (RVTY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Revvity, Inc. (RVTY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Why Is Revvity (RVTY) Down 5.1% Since Last Earnings Report?
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
RVTY gains from strong diagnostics demand and fast-growing Signals software, but China policy pressure and weak research spending temper near-term growth.
Price Targets
Revvity price target lowered to $100 from $110 at Stifel
$100.00
(was $92.30)
Stifel Nicolaus
Revvity price target lowered to $117 from $125 at Baird
$117.00
(was $92.30)
Catherine Ramsey Schulte
·
Robert W. Baird
Revvity price target lowered to $125 from $129 at Baird
$125.00
(was $86.68)
Robert W. Baird
Revvity downgraded to Equal Weight from Overweight at Barclays
$95.00
(was $92.64)
Luke Sergott
·
Barclays
Revvity price target raised to $129 from $123 at Baird
$129.00
(was $103.89)
Catherine Ramsey Schulte
·
Robert W. Baird
Revvity price target raised to $124 from $120 at TD Cowen
$124.00
(was $106.97)
Cowen & Co.
Revvity price target raised to $118 from $112 at Evercore ISI
$118.00
(was $107.09)
Evercore ISI
Revvity price target raised to $118 from $115 at Barclays
$118.00
(was $107.09)
Barclays
Revvity price target raised to $105 from $100 at Jefferies
$105.00
(was $107.05)
Jefferies
Revvity price target raised to $107 from $102 at Wells Fargo
$107.00
(was $100.46)
Brandon Couillard
·
Wells Fargo
Revvity price target raised to $115 from $105 at Barclays
$115.00
(was $100.46)
Luke Sergott
·
Barclays
Revvity initiated with a Neutral at Goldman Sachs
$105.00
(was $99.79)
Evie Koslosky
·
Goldman Sachs
Revvity price target raised to $123 from $122 at Baird
$123.00
(was $97.73)
Robert W. Baird
Revvity price target raised to $105 from $100 at Barclays
$105.00
(was $97.16)
Barclays
Revvity price target raised to $108 from $106 at Evercore ISI
$108.00
(was $95.89)
Evercore ISI
Revvity price target raised to $122 from $121 at Baird
$122.00
(was $98.64)
Catherine Ramsey Schulte
·
Robert W. Baird
Revvity price target lowered to $100 from $110 at Barclays
$100.00
(was $91.76)
Barclays
Revvity price target lowered to $140 from $146 at Raymond James
$140.00
(was $116.60)
Andrew Cooper
·
Raymond James
Revvity downgraded to Market Perform from Outperform at Bernstein
$130.00
(was $113.88)
Eve Burstein
·
Bernstein
KeyBanc Reiterates Overweight Rating on Revvity Inc (RVTY)
$132.00
(was $124.82)
Paul Knight
·
KeyBanc